Screening for prostate cancer: Evidence and perspectives

BJU International

Volumn 88, Issue 8, 2001, Pages 811-817

  Schroder F H ^a   Wildhagen, M F ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; DECISION MAKING; HEALTH CARE POLICY; HUMAN; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PUBLIC HEALTH; QUALITY OF LIFE; REVIEW; SCREENING;

DIAGNOSTIC ERRORS; DISEASE PROGRESSION; EUROPE; HUMANS; MALE; MASS SCREENING; PROFESSIONAL PRACTICE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; TIME FACTORS; UNITED STATES;

EID: 0035163384     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-4096.2001.02449.x     Document Type: Review

References (41)

1. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer
2. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer
3. Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer
4. Comparison of trends in prostate-cancer mortality in England and Wales and the USA
5. Cancer statistics
6. Decrease in prostate cancer mortality following introduction of prostate specific antigen (PSA) screening in the federal state of Tyrol, Austria
7. Screening decreases prostate cancer death. First analysis of the 1988 Quebec prospective randomized controlled trial
8. Screening decreases prostate cancer death. First analysis of the 1988 Quebec prospective randomized controlled trial
9. Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction
10. Cancer surveillance series: Interpreting trends in prostate cancer - Part I. Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates
11. Cancer surveillance series: Interpreting trends in prostate cancer - Part III. Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality
12. Prostate cancer trends, 1973-95
13. Improvement in survival of patients with cancer of the kidney in Europe
14. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer
15. Defining an international research agenda for quality of life in men with prostate cancer
16. Advanced prostate cancer. Course, care, and cost implications
17. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease
18. Long-term survival among men with conservatively treated localized prostate cancer
19. Competing risk analysis of men aged 55-74 years at diagnosis managed conservatively for clinically localized prostate cancer
20. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer
21. What should men know about prostate-specific antigen screening before giving informed consent?
22. Intermediate-term survival results in clinically understaged prostate cancer patients following radical prostatectomy
23. Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region)
24. Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer
25. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer
26. Prostate cancer detection at low prostate specific antigen
27. Prostate-specific antigen-based early detection of prostate cancer - Validation of screening without rectal examination
28. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate
29. Watchful waiting for prostate cancer: It's not for everyone
30. Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (stage T0-4,N1-3,Mo,D1)
31. PSA doubling time of prostate carcinoma managed with watchful observation alone
32. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy correlation with histologic characteristics of the primary cancer
33. American Cancer Society guidelines for the early detection of cancer: Update of early detection guidelines for prostate, colorectal, and endometrial cancers
34. AMA Report 9 of the Council on Scientific Affairs. Screening and early detection of prostate cancer
35. Screening for prostate cancer in American men. American College of Preventive Medicine Practice Policy Statement
36. Clinical guidelines: Part III. Screening for prostate cancer
37. Recommendations on cancer screening in the European Union